Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.

Schmid ST, Koepke J, Dresel M, Hattesohl A, Frenzel E, Perez J, Lomas DA, Miranda E, Greulich T, Noeske S, Wencker M, Teschler H, Vogelmeier C, Janciauskiene S, Koczulla AR.

Int J Chron Obstruct Pulmon Dis. 2012;7:687-96. doi: 10.2147/COPD.S34560. Epub 2012 Sep 28.

2.
3.

Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO.

Koepke J, Dresel M, Schmid S, Greulich T, Beutel B, Schmeck B, Vogelmeier CF, Janciauskiene S, Koczulla AR.

PLoS One. 2015 Jan 30;10(1):e0117497. doi: 10.1371/journal.pone.0117497. eCollection 2015.

4.

SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.

Sorrells S, Camprubi S, Griffin R, Chen J, Ayguasanosa J.

Respir Med. 2015 Apr;109(4):490-9. doi: 10.1016/j.rmed.2015.01.022. Epub 2015 Feb 13.

5.

The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema.

Franciosi AN, McCarthy C, McElvaney NG.

Expert Rev Respir Med. 2015 Apr;9(2):143-51. doi: 10.1586/17476348.2015.1002472. Epub 2015 Jan 19. Review.

PMID:
25598013
6.

The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency.

Stockley RA, Bayley DL, Unsal I, Dowson LJ.

Am J Respir Crit Care Med. 2002 Jun 1;165(11):1494-8.

PMID:
12045122
7.

Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy.

Zamora NP, Pla RV, Del Rio PG, Margaleff RJ, Frias FR, Ronsano JB.

Ann Pharmacother. 2008 May;42(5):640-6. doi: 10.1345/aph.1K505. Epub 2008 Apr 15. Erratum in: Ann Pharmacother. 2008 Jun;42(6):905. Ronsano, Jose Bruono Montoro [corrected Ronsano, Jose Bruno Montoro].

PMID:
18413692
8.

New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy.

Gross B, Grebe M, Wencker M, Stoller JK, Bjursten LM, Janciauskiene S.

Dermatology. 2009;218(4):370-5. doi: 10.1159/000202982. Epub 2009 Feb 16.

9.

Alpha-1 antitrypsin Null mutations and severity of emphysema.

Fregonese L, Stolk J, Frants RR, Veldhuisen B.

Respir Med. 2008 Jun;102(6):876-84. doi: 10.1016/j.rmed.2008.01.009. Epub 2008 Mar 18.

10.

Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin.

Stoller JK, Rouhani F, Brantly M, Shahin S, Dweik RA, Stocks JM, Clausen J, Campbell E, Norton F.

Chest. 2002 Jul;122(1):66-74.

PMID:
12114340
11.

Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase.

Jonigk D, Al-Omari M, Maegel L, Müller M, Izykowski N, Hong J, Hong K, Kim SH, Dorsch M, Mahadeva R, Laenger F, Kreipe H, Braun A, Shahaf G, Lewis EC, Welte T, Dinarello CA, Janciauskiene S.

Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15007-12. doi: 10.1073/pnas.1309648110. Epub 2013 Aug 23.

12.

Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?

Abboud RT, Ford GT, Chapman KR.

Treat Respir Med. 2005;4(1):1-8. Review.

PMID:
15725045
13.

[Alpha-1 antitrypsin deficiency. The experience of Pulido Valente Hospital with augmentation therapy].

Alves Costa C, Santos C.

Rev Port Pneumol. 2009 May-Jun;15(3):473-82. Review. Portuguese.

PMID:
19401796
14.

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency.

Parr DG, Dirksen A, Piitulainen E, Deng C, Wencker M, Stockley RA.

Respir Res. 2009 Aug 13;10:75. doi: 10.1186/1465-9921-10-75.

15.

α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.

Sclar DA, Evans MA, Robison LM, Skaer TL.

Clin Drug Investig. 2012 May 1;32(5):353-60. doi: 10.2165/11631920-000000000-00000.

PMID:
22480280
16.

Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.

Stocks JM, Brantly ML, Wang-Smith L, Campos MA, Chapman KR, Kueppers F, Sandhaus RA, Strange C, Turino G.

BMC Clin Pharmacol. 2010 Sep 30;10:13. doi: 10.1186/1472-6904-10-13.

17.

Augmentation therapy in alpha-1 antitrypsin deficiency.

Heresi GA, Stoller JK.

Expert Opin Biol Ther. 2008 Apr;8(4):515-26. doi: 10.1517/14712598.8.4.515 . Review.

PMID:
18352854
18.

Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency.

Louie SG, Sclar DA, Gill MA.

Ann Pharmacother. 2005 Nov;39(11):1861-9. Epub 2005 Oct 11. Review. Erratum in: Ann Pharmacother. 2005 Dec;39(12):2143.

PMID:
16219903
19.

Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin.

Piitulainen E, Bernspång E, Björkman S, Berntorp E.

Eur J Clin Pharmacol. 2003 Jun;59(2):151-6. Epub 2003 May 1.

PMID:
12728289
20.

Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency.

Campbell EJ, Campbell MA, Boukedes SS, Owen CA.

J Clin Invest. 1999 Aug;104(3):337-44.

Supplemental Content

Support Center